Patiënten

Patientenzorg

Gezond weefsel beter sparen Dat is het voordeel van protonentherapie.

Bekijk
Waarom protonentherapie Algemene informatie Soorten kanker Ervaringen van patiënten Tips en adviezen Second opinion Jongvolwassen en kanker
Locatie en contactgegevens Wat neemt u mee Vervoer en overnachten Compliment of klacht
Kosten en verzekering Uw dossier
Research

Research

HollandPTC research focuses on proving the benefit of proton therapy and to further improve its efficacy.

View
Our principal investigators into proton therapy Research program Protonpost articles Organisation & collaborations
Pre-clinical and clinical facilities
Doing proton research or use our facilities Our research database: how to request data Practical information on Varian projects R&D communication box
HollandPTC

HollandPTC

Voor de beste protonentherapie van nu en later

Over HollandPTC
Onze visie: Samen beter, beter samen Ons team
Vrienden van Cliëntenraad

SAMEN BETER, BETER SAMEN

Patiënten

Patientenzorg

Gezond weefsel beter sparen Dat is het voordeel van protonentherapie.

Bekijk
Over de behandeling Waarom protonentherapie Algemene informatie Soorten kanker Ervaringen van patiënten Tips en adviezen Second opinion Jongvolwassen en kanker
Uw bezoek aan HollandPTC Locatie en contactgegevens Wat neemt u mee Vervoer en overnachten Compliment of klacht
Praktische informatie Kosten en verzekering Uw dossier
Research

Research

HollandPTC research focuses on proving the benefit of proton therapy and to further improve its efficacy.

View
Research at HollandPTC Our principal investigators into proton therapy Research program Protonpost articles Organisation & collaborations
Facilities Pre-clinical and clinical facilities
How to do research or use our facilities Doing proton research or use our facilities Our research database: how to request data Practical information on Varian projects R&D communication box
HollandPTC

HollandPTC

Voor de beste protonentherapie van nu en later

Over HollandPTC
Over HollandPTC Onze visie: Samen beter, beter samen Ons team
Vrienden van Cliëntenraad

Principal investigator prof. Marco van Vulpen

“We are facing a paradigm shift in radiotherapy, moving from ‘elective’ to an ‘ablative’, more surgical-like, approach, with fewer treatment fractions. This is enabled by on-board imaging with optimal contrast between tumor and normal tissues, on-line AI-based contouring, on-line treatment planning and decision loops to enable a daily new treatment plan. Several innovations which enable such a tailored and personalized approach are clinically introduced, like the MRI-linac and proton therapy with advanced on-board CT. Here, the patient especially benefits.”

Research focus

My research focuses on the development and clinical introduction of new radiotherapy techniques, such as the MRI accelerator and proton therapy, especially in the context of determining the clinical value, like in quality of life, clinical outcome, capacity, or health technology assessment.

Scientific career

Current positions and membership:

  • Medical director of HollandPTC
  • Professor in radiotherapy at Leiden UMC, Erasmus MC, TU Delft and Medical Delta
  • Chair of the research consortium Leiden UMC, Erasmus MC and TU Delft
  • Adjunct professor of radiotherapy and a member of the medical staff at the MD Anderson Cancer Center in Houston, Texas

Past positions and education

  • Head of the radiotherapy department at UMC Utrecht, where a 1.5 Tesla MRI linear accelerator was developed.
  • Chairman of the international consortium, ATLANTIC, for the global introduction of the MRI accelerator.
  • Specialization in Radiation Oncology at the University of Utrecht, appointed professor in 2011.
    Inaugural lecture entitled ‘The end of radiotherapy’, describing implementation of innovations and improving the care paths in oncology.
  • PhD research at the University of Utrecht on ‘Hyperthermia for prostate cancer’ (2003)
  • Medicine at the University of Amsterdam (VUmc)

Publications